Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | NR1D2 | Q14995 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323821 | 1.00 | CCR1 (0.35) | CCR1NR1D1NR1H3NR1D2MEN1 | |
| SCHEMBL1323469 | 0.85 | CCR1 (0.35) | CCR1 | |
| SCHEMBL1323470 | 0.85 | CCR1 (0.35) | CCR1 | |
| SCHEMBL5487866 | 0.83 | CCR1 (0.33) | CCR1NR1D1 | |
| SCHEMBL5487869 | 0.83 | CCR1 (0.33) | CCR1NR1D1 | |
| SCHEMBL18601633 | 0.82 | CCR1 (0.34) | CCR1 | |
| SCHEMBL18601634 | 0.82 | CCR1 (0.34) | CCR1 | |
| SCHEMBL6362657 | 0.81 | CCR1 (0.38) | CCR1L3MBTL1 | |
| SCHEMBL7733509 | 0.79 | CCR1 (0.42) | CCR1 | |
| SCHEMBL7733512 | 0.79 | CCR1 (0.42) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885NR1D1 1453/4885NR1H3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.